Clene Inc. Files 8-K, Updates Corporate Information
Ticker: CLNN · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1822791
| Field | Detail |
|---|---|
| Company | Clene Inc. (CLNN) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-info, filing-update
TL;DR
Clene Inc. filed an 8-K updating its address and confirming former name. Nothing major.
AI Summary
Clene Inc. filed an 8-K on April 16, 2024, reporting on other events and financial statements. The filing details the company's principal executive offices located at 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah, 84121, and its phone number is 801-676-9695. The company was formerly known as Chelsea Worldwide Inc. until August 27, 2020.
Why It Matters
This filing provides essential corporate and contact information for Clene Inc., serving as an official update for investors and stakeholders regarding its operational base and historical name changes.
Risk Assessment
Risk Level: low — The filing is primarily administrative, updating corporate information and not indicating any significant financial or operational changes.
Key Players & Entities
- Clene Inc. (company) — Registrant
- April 16, 2024 (date) — Date of Report
- 6550 South Millrock Drive, Suite G50 (address) — Principal executive offices
- Salt Lake City, Utah 84121 (address) — Principal executive offices
- 801-676-9695 (phone_number) — Registrant's phone number
- Chelsea Worldwide Inc. (company) — Former company name
- August 27, 2020 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing by Clene Inc.?
The primary purpose of this 8-K filing is to report on other events and financial statements, and to update corporate information such as the principal executive offices and former company name.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 16, 2024.
What is Clene Inc.'s principal executive office address?
Clene Inc.'s principal executive office is located at 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah 84121.
What was Clene Inc.'s former company name?
Clene Inc.'s former company name was Chelsea Worldwide Inc.
On what date did Clene Inc. change its name from Chelsea Worldwide Inc.?
Clene Inc. changed its name from Chelsea Worldwide Inc. on August 27, 2020.
Filing Stats: 694 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2024-04-16 16:06:45
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value CLNN The Nasdaq Capital M
- $11.50 — e-half of one share of Common Stock for $11.50 per share CLNNW The Nasdaq Capital
Filing Documents
- clnn20240415_8k.htm (8-K) — 30KB
- ex_653961.htm (EX-99.1) — 7KB
- ex_654698.htm (EX-99.2) — 2KB
- ex_653935.htm (EX-99.3) — 22KB
- a01.jpg (GRAPHIC) — 72KB
- a02.jpg (GRAPHIC) — 96KB
- a03.jpg (GRAPHIC) — 107KB
- a04.jpg (GRAPHIC) — 100KB
- a05.jpg (GRAPHIC) — 86KB
- a06.jpg (GRAPHIC) — 86KB
- a07.jpg (GRAPHIC) — 98KB
- a08.jpg (GRAPHIC) — 93KB
- a09.jpg (GRAPHIC) — 94KB
- a10.jpg (GRAPHIC) — 118KB
- b01.jpg (GRAPHIC) — 148KB
- 0001437749-24-012182.txt ( ) — 1725KB
- clnn-20240416.xsd (EX-101.SCH) — 4KB
- clnn-20240416_def.xml (EX-101.DEF) — 13KB
- clnn-20240416_lab.xml (EX-101.LAB) — 17KB
- clnn-20240416_pre.xml (EX-101.PRE) — 13KB
- clnn20240415_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. In connection with the press release discussed under Item 8.01 in this Current Report on Form 8-K, on April 16, 2024, Clene Inc. (the "Company") released a presentation (the "Presentation") and poster (the "Poster") on its website, invest.clene.com. The Presentation and Poster discuss the clinical results of CNM-Au8 treatment in the Company's VISIONARY-MS trial long-term extension ("LTE") for multiple sclerosis ("MS"). A copy of the Presentation and Poster are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On April 16, 2024, the Company issued a press release announcing evidence for CNM-Au8 as a treatment for repair and remyelination in MS presented in the Emerging Science Session at the 2024 American Academy of Neurology ("AAN") Annual Meeting. A copy of the press release is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 VISIONARY-MS LTE Presentation. 99.2 VISIONARY-MS LTE Poster. 99.3 Press release, dated April 16, 2024, announcing evidence for Clene's CNM-Au8 as a treatment for repair and remyelination in MS presented in the Emerging Science Session at the 2024 AAN Annual Meeting. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CLENE INC. Date: April 16, 2024 By: /s/ Robert Etherington Robert Etherington President and Chief Executive Officer 2